Crowell Represents Marshall Wace in $41.5 million Series B Financing of Parse Biosciences
February 16, 2022
San Francisco – February 16, 2022: Crowell & Moring represented Marshall Wace, a global alternative investment manager, in a $41.5 million Series B round of funding of Parse Biosciences. Marshall Wace co-led the transaction with Janus Henderson Investors, with Soleus Capital, Logos Capital and Bioeconomy Capital also participating. Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research through their pioneering approach for single cell sequencing. Single-cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. The transaction was led by partners Jon O’Connell (San Francisco) and Anne Li (New York) and included partners Rashad Morgan (Chicago), counsel Matt Pelnar (San Francisco), and associates Karla Arias (Washington, D.C.) and Justin Lurie (New York).